Atyr Pharma Inc

NASDAQ:LIFE   3:35:59 PM EDT
10.25
-0.01 (-0.10%)
Products, Regulatory

aTyr Pharma Reports Positive Data from Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis

Published: 09/13/2021 11:39 GMT
Atyr Pharma Inc (LIFE) - Atyr Pharma Announces Positive Data From Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for Atyr1923 in Pulmonary Sarcoidosis.
Atyr Pharma Inc - Trial Met Primary Endpoint, Atyr1923 Was Safe and Well-tolerated.
Atyr Pharma Inc - Efficacy Observed in Key Endpoints Including Steroid Reduction of 58% in 5.0 Mg/kg Treatment Group.